DGP-IgA is an antibody test that detects immune reactions to deamidated gliadin, a component of gluten. It serves as a marker for celiac disease, especially when used with tTG-IgA.
Gliadin (deaminiert) IgA is often considered in the context of tiredness, reduced capacity, brain fog, or chronic exhaustion. This short overview clarifies what the marker can contribute, where its limits are, and when symptom or illness context becomes more important.
Gliadin (deaminiert) IgA becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
Gliadin (deaminiert) IgA does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
Deamidated gliadin IgA antibodies (DGP-IgA) are immune proteins produced by the body in response to deamidated gliadin, a modified form of the gluten protein found in wheat, barley, and rye. This test is primarily used in the diagnosis of celiac disease, an autoimmune disorder triggered by gluten ingestion.
DGP-IgA is considered a highly specific serological marker, often recommended alongside tissue transglutaminase IgA (tTG-IgA) to improve diagnostic accuracy, particularly in young children and individuals with IgA deficiency. Testing is most reliable when the patient has been consuming a gluten-containing diet prior to blood draw.
A negative result, typically defined as a value below the laboratory’s cutoff (commonly <20 arbitrary units or a qualitative “negative”), suggests that there is no significant IgA antibody response to deamidated gliadin. This makes celiac disease unlikely, provided the individual has been on a gluten-containing diet. In patients with IgA deficiency, a negative DGP-IgA alone may be falsely negative, so additional tests may be required.
A positive DGP-IgA result indicates an elevation in antibodies to deamidated gliadin, which is consistent with gluten-induced immune activation and suggests celiac disease. Elevated levels can be seen in untreated celiac disease and tend to decrease after starting a strict gluten-free diet. This marker is particularly useful when tTG-IgA is borderline or negative but clinical suspicion remains high.
This result is not specific for ME/CFS or Long COVID. Read it together with the clinical question, symptoms, related findings and the laboratory reference range rather than in isolation.
Practical details are separated from the general FAQ so they are easier to find.
Gliadin (deaminiert) IgA becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
Both are antibodies used in celiac disease testing. tTG-IgA is the most common screening test, while DGP-IgA may be used as an additional marker to improve detection, especially in children under 2 years or in cases where there is IgA deficiency. Some studies suggest DGP-IgG can be helpful in IgA-deficient patients.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
You now know which questions can matter when reading this result. With Elara you can keep the value and its surrounding context together over time.
Save the lab value with its date so individual measurements do not get lost.
See previous measurements together instead of relying on a single snapshot.
View Deamidated Gliadin IgA Antibodies (DGP-IgA) alongside symptom, energy, sleep and PEM entries without assuming one caused the other.
Export your history as a PDF — structured for the next check-up.
A positive DGP-IgA means that your immune system is producing antibodies against deamidated gliadin, which is a sign of a reaction to gluten. This often indicates celiac disease, although a small number of positive results may occur in other conditions or even in healthy individuals. A positive test usually leads to further evaluation, such as an intestinal biopsy.
Yes, it is essential to be on a gluten-containing diet for at least several weeks before the test. If you are already gluten-free, your antibody levels may drop, leading to a false-negative result. Your doctor can advise on the exact duration of gluten challenge needed.
Yes, in people with celiac disease, DGP-IgA levels typically decline once a strict gluten-free diet is started. Monitoring DGP-IgA can sometimes be used to assess dietary compliance and disease activity, although other tests like tTG-IgA are more commonly used for this purpose.
Gliadin (deaminiert) IgA does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
For many fatigue-related, inflammatory, hormonal, or recovery-linked markers, interpretation becomes stronger when symptoms, exertion response, and daily function are considered together.
Gliadin (deaminiert) IgA is rarely meaningful in isolation when fatigue, brain fog, or unstable capacity are central. The fatigue hub provides the broader lab-and-symptom context.
If symptoms worsen after activity with a delay, PEM often explains more than an isolated lab value alone.
Questionnaires help connect biomarkers to symptom patterns, functional limits, and patient-reported change over time.
Markers from the same system can add useful context when a single lab value is hard to interpret on its own.
No individual medical review is documented.
This English content was created with AI assistance and automatically validated. This is not an individual medical review.
This information does not replace medical advice. Lab values should be assessed in the context of your medical history, the reason for testing and other findings. Elara provides health information for orientation — not diagnoses or treatment decisions.
Bring your lab values, symptoms and energy into one shared context — so you walk into your next appointment more informed and structured.
